Published:December 16, 2022DOI:



      Droperidol is a butyrophenone, with antiemetic, sedative, anxiolytic, and analgesic properties. Although droperidol was once widely used in both emergency and perioperative settings, use of the medication declined rapidly after a 2001 US Food and Drug Administration (FDA) boxed warning called the medication's safety into question.


      The purpose of this clinical review was to provide evidence-based answers to questions about droperidol's safety and to examine its efficacy in its various clinical indications.


      Droperidol is an effective sedative, anxiolytic, analgesic, and antiemetic medication. As a sedative, when compared with haloperidol, droperidol has faster onset, as well as greater efficacy, in patients experiencing acute psychosis, with no increase in adverse events. As an antiemetic, droperidol has been found to have equal or greater efficacy in reducing nausea and vomiting than ondansetron and metoclopramide, with similar adverse effects and the added effect of reducing the need for rescue analgesia in these patients. As an analgesic, droperidol is effective for migraines and has opioid-sparing effects when used to treat abdominal pain. Droperidol is a particularly useful adjunct in patients who are opioid-tolerant, whose pain is often difficulty to manage adequately.


      Droperidol seems to be effective and safe, despite the boxed warning issued by the FDA. Droperidol is a powerful antiemetic, sedative, anxiolytic, antimigraine, and adjuvant to opioid analgesia and does not require routine screening with electrocardiography when used in low doses in otherwise healthy patients before administration in the emergency department.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Emergency Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Compound summary for CID 3168, droperidol. National Center for Biotechnology Information. Accessed December 23, 2022.

        • Richards JR
        • Richards IN
        • Ozery G
        • Derlet RW.
        Droperidol analgesia for opioid-tolerant patients.
        J Emerg Med. 2011; 41: 389-396
        • Horowitz BZ
        • Bizovi K
        • Moreno R.
        Droperidol—behind the black box warning.
        Acad Emerg Med. 2002; 9: 615-618
        • Kramer KJ.
        The surprising re-emergence of droperidol.
        Anesth Prog. 2020; 67: 125-126
        • Kao LW
        • Kirk MA
        • Evers SJ
        • Rosenfeld SH.
        Droperidol, QT prolongation, and sudden death: what is the evidence?.
        Ann Emerg Med. 2003; 41: 546-558
      2. Briggs B. Stop the madness, and bring back droperidol. Emergency Medicine News. Published October 27, 2021. Accessed January 17, 2022.

        • Ludwin DB
        • Shafer SL.
        Con: the black box warning on droperidol should not be removed (but should be clarified!).
        Anesth Analg. 2008; 106: 1418-1420
        • Perkins J
        • Ho JD
        • Vilke GM
        • DeMers G.
        American academy of emergency medicine position statement: safety of droperidol use in the emergency department.
        J Emerg Med. 2015; 49: 91-97
        • Cole JB
        • Lee SC
        • Martel ML
        • Smith SW
        • Biros MH
        • Miner JR.
        The incidence of QT prolongation and torsades des pointes in patients receiving droperidol in an urban emergency department.
        West J Emerg Med. 2020; 21: 728-736
        • Gaw CM
        • Cabrera D
        • Bellolio F
        • Mattson AE
        • Lohse CM
        • Jeffery MM.
        Effectiveness and safety of droperidol in a united states emergency department.
        Am J Emerg Med. 2020; 38: 1310-1314
        • Martel ML
        • Driver BE
        • Miner JR
        • Biros MH
        • Cole JB.
        Randomized double-blind trial of intramuscular droperidol, ziprasidone, and lorazepam for acute undifferentiated agitation in the emergency department.
        Acad Emerg Med. 2021; 28: 421-434
        • Lischke V
        • Behne M
        • Doelken P
        • Schledt U
        • Probst S
        • Vettermann J.
        Droperidol causes a dose-dependent prolongation of the QT interval.
        Anesth Analg. 1994; 79: 983-986
        • Nuttall GA
        • Malone AM
        • Michels CA
        • et al.
        Does low-dose droperidol increase the risk of polymorphic ventricular tachycardia or death in the surgical patient?.
        Anesthesiology. 2013; 118: 382-386
        • Calver L
        • Page CB
        • Downes MA
        • et al.
        The safety and effectiveness of droperidol for sedation of acute behavioral disturbance in the emergency department.
        Ann Emerg Med. 2015; 66 (e1): 230-238
        • Calver L
        • Isbister GK.
        Parenteral sedation of elderly patients with acute behavioral disturbance in the ED.
        Am J Emerg Med. 2013; 31: 970-973
        • Page CB
        • Parker LE
        • Rashford SJ
        • Kulawickrama S
        • Isoardi KZ
        • Isbister GK.
        Prospective study of the safety and effectiveness of droperidol in elderly patients for pre-hospital acute behavioural disturbance.
        Emerg Med Australas. 2020; 32: 731-736
        • Rappaport BA.
        FDA response to droperidol black box warning editorials.
        Anesth Analg. 2008; 106: 1585
        • Thomas MC
        • Musselman ME
        • Shewmaker J.
        Droperidol for the treatment of acute migraine headaches.
        Ann Pharmacother. 2015; 49: 233-240
        • Braude D
        • Soliz T
        • Crandall C
        • Hendey G
        • Andrews J
        • Weichenthal L.
        Antiemetics in the ED: a randomized controlled trial comparing 3 common agents.
        Am J Emerg Med. 2006; 24: 177-182
        • Resnick M
        • Burton BT.
        Droperidol vs. haloperidol in the initial management of acutely agitated patients.
        J Clin Psychiatry. 1984; 45: 298-299
        • Thomas H
        • Schwartz E
        • Petrilli R.
        Droperidol versus haloperidol for chemical restraint of agitated and combative patients.
        Ann Emerg Med. 1992; 21: 407-413
        • Domino KB
        • Anderson EA
        • Polissar NL
        • Posner KL.
        Comparative efficacy and safety of ondansetron, droperidol, and metoclopramide for preventing postoperative nausea and vomiting: a meta-analysis.
        Anesth Analg. 1999; 88: 1370-1379
        • Furyk JS
        • Meek RA
        • Egerton-Warburton D.
        Drugs for the treatment of nausea and vomiting in adults in the emergency department setting.
        Cochrane Database Syst Rev. 2015; 2015CD010106
        • Lee C
        • Greene SL
        • Wong A.
        The utility of droperidol in the treatment of cannabinoid hyperemesis syndrome.
        Clin Toxicol (Phila). 2019; 57: 773-777
        • Silberstein SD
        • Young WB
        • Mendizabal JE
        • Rothrock JF
        • Alam AS.
        Acute migraine treatment with droperidol: a randomized, double-blind, placebo-controlled trial.
        Neurology. 2003; 60: 315-321
        • Miner JR
        • Fish SJ
        • Smith SW
        • Biros MH.
        Droperidol vs. prochlorperazine for benign headaches in the emergency department.
        Acad Emerg Med. 2001; 8: 873-879
        • Weaver CS
        • Jones JB
        • Chisholm CD
        • et al.
        Droperidol vs prochlorperazine for the treatment of acute headache.
        J Emerg Med. 2004; 26: 145-150
        • Miller AC
        • Khan AM
        • Castro Bigalli AA
        • et al.
        Neuroleptanalgesia for acute abdominal pain: a systematic review.
        J Pain Res. 2019; 12: 787-801